SB 878 is a broad pharmacy and health-benefits bill that revises Missouri law on several pharmaceutical and device-related topics. A major portion of the bill updates the state’s rules for over-the-counter methamphetamine precursor drugs such as pseudoephedrine, ephedrine, and phenylpropanolamine. It keeps the existing purchase limits in place but raises the annual limit from 43 grams to 61.2 grams, continues the 7.2-gram 30-day limit and 3.6-gram 24-hour limit, requires these products to remain behind the pharmacy counter, and adds a monthly fee structure for manufacturers tied to the real-time pseudoephedrine tracking system. The bill also revises the criminal penalties for unlawful sales and related violations under section 579.060.
The bill also expands and clarifies pharmacist authority. It updates the definition of the practice of pharmacy, changes how pharmacists may provide influenza, group A strep, and COVID-19 medication therapy services, and authorizes pharmacists to prescribe certain medical devices that are approved by joint rule. It separately allows pharmacists, under board-approved procedures, to dispense ivermectin and hydroxychloroquine without a prescription. In addition, it creates emergency-disaster flexibility for Missouri pharmacies shipping prescription drugs into other states or territories during declared emergencies, subject to compliance with the receiving jurisdiction’s emergency rules and federal law.
SB 878 further addresses insurance coverage and pharmacy-benefit practices. It prohibits health carriers and pharmacy benefit managers from discriminating against 340B covered entities through lower reimbursement, different terms, audit burdens, or other practices that interfere with the value of 340B discounts, and authorizes civil penalties for violations. It also bars health plans from favoring opioids over nonopioid medications for acute or chronic pain by denying coverage, requiring opioid step therapy, or imposing higher cost-sharing on the nonopioid drug. The bill additionally requires coverage of prescribed home blood pressure monitoring devices and related training services for pregnant and postpartum women when medically appropriate, a provision designated as “Nora’s Law.”
The overall sentiment reflected in the available voting history is strongly favorable: the Senate passed the bill on third reading by a 28-0 vote. No committee transcripts were provided, so there is no recorded committee debate to indicate opposition or amendment concerns in the materials supplied. The unanimous floor vote suggests broad support for the bill’s pharmacy, public health, and insurance coverage provisions.
The main points of contention, based on the bill’s content, are likely to center on the pseudoephedrine changes, the authority granted to pharmacists to dispense ivermectin and hydroxychloroquine without a prescription, and the restrictions imposed on insurers and pharmacy benefit managers in the 340B context. The bill also contains several rulemaking directives to state boards and the department of commerce and insurance, which may raise questions about administrative authority and implementation. However, no explicit opposition is documented in the provided discussion materials.
SB 878 repeals and reenacts multiple Missouri statutes governing pharmacy practice, methamphetamine precursor controls, 340B reimbursement practices, and health insurance coverage mandates. It amends sections 195.417, 338.010, 338.012, and 579.060, and creates new sections 338.206, 338.208, 338.312, 376.417, 376.1280, and 376.1960. The bill affects pharmacists, pharmacies, manufacturers of pseudoephedrine-type products, health carriers, pharmacy benefit managers, covered entities participating in the federal 340B program, and enrollees in health benefit plans. It also directs multiple state agencies and boards to promulgate implementing rules, including the Board of Pharmacy, the State Board of Registration for the Healing Arts, and the Department of Commerce and Insurance.
The available voting record indicates clear bipartisan or at least broad chamber support, with the Senate passing the bill 28-0 on third reading. No committee transcript was provided, so the record does not show detailed debate, but the unanimous vote suggests the bill was viewed favorably overall. The bill’s public health, pharmacy access, and insurance coverage provisions appear to have been acceptable to the chamber as a package.
The most likely areas of contention are the bill’s expansion of pharmacist authority to dispense ivermectin and hydroxychloroquine without a prescription, the increase in the annual pseudoephedrine purchase threshold, and the new manufacturer fee structure supporting the tracking system. The 340B nondiscrimination provisions may also draw concern from insurers and pharmacy benefit managers because they limit reimbursement practices, audit requirements, and network conditions. Finally, the opioid/nonopioid coverage mandate and the new maternity blood pressure monitor coverage requirement impose new insurance obligations that could be debated by health plans and budget-focused policymakers.